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The drug development process—regulated by the U.S. Food and Drug
Administration (FDA)—is complex, lengthy, and costly. For years, 
reformers have sought more liberal access to potential drug treatments
that have not yet reached the final stages of the process. “Right to Try”
laws and the FDA’s expanded access program are among some of the
government measures designed to allow terminally ill patients to obtain 
investigational drugs before they receive FDA approval. This Article 
explores the strengths and shortcomings of some of the measures
undertaken by state and federal governments, while highlighting the 
policy struggle between providing individuals early access to potentially 
life-saving drugs and maintaining the necessary government oversight to
ensure consumer safety.
INTRODUCTION
Today, as the world faces the unprecedented global health crisis
related to the novel coronavirus—COVID-19—pandemic, many are 
asking the critical question of whether there is an effective treatment for
those who have been infected by the virus. Thus far, none have been
identified. President Donald Trump has held a major role in the effort to
explore potential treatment options, repeatedly advocating for the
unintended use of various drugs whose effectiveness on the coronavirus
* Quinnipiac University School of Law, JD ‘19. I would like to thank Professor Leonard
Dwarica for inspiring the premise of this Article. I would also like to thank my friends and
family for their unwavering support. Finally, I would like to extend my appreciation to the staff 
of the Western New England Law Review for their assistance in the editing of this Article.
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170 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
has not been proven.1 The President’s fervent insistence that patients have
the right to seek out unconventional and unapproved treatments during
this health crisis underscores a much larger discussion surrounding the
nation’s complex drug approval process and the concern that it may 
actually impede access to life-saving drugs.
The U.S. Food and Drug Administration (FDA), the oldest consumer
protection agency in the United States, is predominantly responsible for
overseeing the nation’s drug and medical device markets.2 The Food,
Drug, and Cosmetic Act (FDCA), through which Congress delegated its
enforcement power to the FDA, requires all drugs to be approved for
safety and efficacy by the FDA prior to their release into the consumer 
market.3 A pharmaceutical drug’s journey from its preclinical to market-
ready stage is long and arduous. It is often estimated that the average
length for the drug development process is upwards of ten years; the 
number popularly expressed is twelve years.4 Drug manufacturers can
spend up to five billion dollars to bring a new treatment to market.5 
Patients suffering from terminal illnesses, or who are simply desperate for
a treatment, often do not have the luxury of waiting for such an extensive 
1. See, e.g., Remarks by President Trump, Vice President Pence, and Members of the
Coronavirus Task Force in Press Briefing, WHITE HOUSE (Apr. 15, 2020) 
https://www.whitehouse.gov/briefings-statements/remarks-president-trump-vice-president-
pence-members-coronavirus-task-force-press-briefing-26/ [https://perma.cc/9PDK-CZ5S].  
President Trump, on numerous occasions during press briefings regarding the coronavirus,
touted drugs including chloroquine, hydroxychloroquine, and remdesivir as promising
treatment solutions against COVID-19. Id.
2. The History of FDA’s Fight for Consumer Protection and Public Health, FDA (June
29, 2018) https://www.fda.gov/about-fda/history-fdas-fight-consumer-protection-and-public-
health [https://perma.cc/BK4H-XWWU].
3. See generally 21 U.S.C. § 301–399i (2018).
4. Gail A. Van Norman, Drugs, Devices, and the FDA: Part 1, 1 JACC: BASIC TO 
TRANSLATIONAL SCI. 170, 171 (2016), https://basictranslational.onlinejacc.org/content/ 
btr/1/3/170.full.pdf [https://perma.cc/MVA8-HPFC]; Richard C. Mohs & Nigel H. Greig, Drug
Discovery and Development: Role of Basic Biological Research, 3 ALZHEIMER'S & DEMENTIA:
TRANSLATIONAL RES. & CLINICAL INTERVENTIONS 651, 651 (2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725284/pdf/main.pdf
[https://perma.cc/Q8L9-BCUN]; BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT: THE
PROCESS BEHIND NEW MEDICINES, PHRMA 1, http://phrma-docs.phrma.org/ 
sites/default/files/pdf/rd_brochure_022307.pdf [https://perma.cc/8ELA-JHHP]; The Drug
Development and Approval Process, FDAREVIEW.ORG, https://www.fdareview.org/issues/the-
drug-development-and-approval-process/ [https://perma.cc/2U39-DDAG].
5. MARK FLATTEN, DEAD ON ARRIVAL: FEDERAL “COMPASSIONATE USE” LEAVES 




     
 
     
      
        
    
          
        
    
     
      
      
     
       
 
         
      
      
 
         
       
       
 
     
    
    
         
    
    
          
        
 
                 
     
               
         
       
           
  
         
   
   
1712020]	$ A HARD PILL TO SWALLOW
period of time to receive medication that could potentially save their lives.
Patients and advocates continue to fight for the right to access
investigational drugs before they are on the market; this effort is
colloquially referred to as the “Right to Try” (RTT) movement.6 
This Article begins by providing an overview of the FDA’s lengthy
drug development and approval process. Next, it explores various
governmental measures aimed at creating emergency use exceptions to 
either abbreviate or circumvent such process—including the FDA’s 
expanded access program, state RTT laws, and the federal RTT Act—and 
evaluates their effectiveness in improving patient access to drugs in 
emergency situations that would not otherwise have been available.
Finally, this Article briefly examines the implications of these measures
in light of the COVID-19 health crisis.
I.	' TRIALS AND TRIBULATIONS: THE STEPS OF DRUG DEVELOPMENT
The successful production of a new pharmaceutical drug requires an 
enormous amount of time and expense on the part of the manufacturer,
primarily due to the extensive statutory and regulatory schemes governing 
the drug’s manufacturing and testing procedures.7 The FDA is intimately
involved throughout the life of the drug, from its inception to its eventual 
arrival on the market, and beyond. An overview of the standard process
is outlined below.
The drug development and approval process can be broken down into 
five basic steps: (1) discovery and development, (2) preclinical research, 
(3) clinical research, (4) FDA review, and (5) post-market safety
monitoring.8 During the discovery and development phase, researchers
identify promising compounds for development and conduct preliminary 
experiments to gather information on various basic properties, including 
potential benefits, best dosage, and delivery method.9 Prior to testing on
humans, researchers must determine whether a drug is toxic, or has the 
6. See Tamara J. Patterson, Note, The Cost of Hope at the End of Life: An Analysis of
Right-To-Try Statutes, 105 KY L.J. 685, 686 (2017).
7. This Article focuses on the development process for a new drug through a new drug
application; it does not address the development of generic drugs, for which a different,
abbreviated process is utilized, nor does it address the development of biologics through a 
biologics license application. See 21 U.S.C. § 355(j) (2018); see generally 21 C.F.R. §§ 320– 
320.63, 600–680 (2020).
8.	$See Drug Development and Approval Process, supra note 4.
9. Step 1: Discovery and Development, FDA, https://www.fda.gov/patients/drug-
development-process/step-1-discovery-and-development [https://perma.cc/47VZ-XKZS].
 
      
 
          
       
      
        
      
      
     
    
          
       
       
        
      
    
       
      
  
      
        
  
 
   
  
               
       
            
        
 
        
 
  
     
     
 
     
   
      
  
   
  
   
   
172 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
potential to cause serious harm.10 This is done in the next phase,
preclinical research, wherein the sponsor11 screens the drug for toxicity in
animals.12 Following preclinical testing, researchers analyze the findings
and decide whether to test the drug in humans.13 When the sponsor
decides to test the drug’s therapeutic potential on humans, it must file an
Investigational New Drug (IND) application containing information in
three areas: animal pharmacology and toxicology studies, manufacturing
information, and clinical protocols and investigator information for
proposed clinical studies.14 After submitting an IND to the FDA, the
sponsor must wait thirty days before it may begin clinical trials.15 During
this time, the FDA reviews the IND “for safety to assure that research 
subjects will not be subjected to unreasonable risk.”16 If the FDA does 
not object to the IND within the thirty days, the IND becomes effective 
and the sponsor may begin testing on humans through clinical trials.17 
Perhaps the most critical stage of the development process is the 
clinical research stage, which is further broken down into three phases. In 
Phase I, approximately twenty to eighty healthy individuals are treated 
with the drug, predominantly to establish its safety and profile; this phase
typically takes about one year.18 In Phase II, the drug’s efficacy is 
assessed on one hundred to three hundred patient volunteers with the 
10. Step 2: Preclinical Research, FDA, https://www.fda.gov/patients/drug-development-
process/step-2-preclinical-research [https://perma.cc/9MSL-VG59].
11. A sponsor of a drug is “a person who takes responsibility for and initiates a clinical
investigation. The sponsor may be an individual or pharmaceutical company, governmental 
agency, academic institution, private organization, or other organization. The sponsor does not
actually conduct the investigation unless the sponsor is a sponsor-investigator.” 21 C.F.R. §
511.3.




13. Step 2: Preclinical Research, supra note 10.
14. See Investigational New Drug (IND) Application, FDA,
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
[https://perma.cc/W4KP-53HW]; see also FDA Drug Approval Process, DRUGS.COM, 
https://www.drugs.com/fda-approval-process.html [https://perma.cc/68EV-G9JP].
15. Investigational New Drug (IND) Application, supra note 14.
16. Id.
17. See IND Application Procedures: Overview, FDA, 
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-
procedures-overview [https://perma.cc/6RR2-5X6U].
18. Step 3: Clinical Research, FDA, https://www.fda.gov/patients/drug-development-
process/step-3-clinical-research [https://perma.cc/24KR-ZBCF].
 
     
 
        
       
        
     
          
     
      
           
     
           
         
     
         
        
        
     
          
     
 
           
      
       
              
    
            
      
     
      
 
 
       
     
 
    
    
    
         
   
             
     
    
1732020] A HARD PILL TO SWALLOW
specific condition or disease the drug is aimed to treat (the target 
population); this phase typically lasts approximately two years.19 At the
end of this phase, the manufacturer will meet with the FDA to discuss,
among other things, any concerns the FDA may have and the protocols
for Phase III if the FDA deems the drug is ready to proceed.20 Phase III
is the most extensive part of the drug development process. Several 
thousand patients in healthcare facilities such as clinics and hospitals are
monitored for the drug’s efficacy and additional side effects.21 On
average, this phase lasts about three years.22 
Once Phase III is complete, the manufacturer must file a new drug
application (NDA).23 The application, which entails thousands of pages
of material—including all animal and human data, side effects, dosing, 
and directions for use, among other data—must comply with the
requirements set forth in 21 U.S.C. § 355(b).24 The FDA must review 
the application within 180 days of submission and either approve the
application or notify the applicant of an opportunity for a hearing for
further determination.25 Once approved, the drug may be marketed with
FDA regulated labeling, and the drug becomes available for physicians to 
prescribe.26 
The process does not end there, however. The FDCA provides the
FDA with the authority to require manufacturers to conduct post-market
safety studies and trials to continue monitoring possible risks associated
with the drugs.27 The FDA is required to publish an annual notice in the
Federal Register, containing information on the performance of post-
market studies and clinical trials that the FDA requires, or has requested,
of manufacturers.28 Safety monitoring continues for the life of the drug 
through tracking reports of adverse events, which are unfavorable and 
unintended signs, symptoms, or diseases associated with the use of the
19. Id.
20. Drug Development and Approval Process, supra note 4.
21. FDA Drug Approval Process, supra note 14.
22. Id.
23. 21 U.S.C. § 355(a) (2018).
24. Id. at § 355(b).
25. Id. at § 355(c)(1).
26. Drug Development and Approval Process, supra note 4; FDA Drug Approval Process, 
supra note 14.
27. See Food and Drug Administration Amendment Acts of 2007, Pub. L. No. 110-85,
§ 901 et seq, 121 Stat. 823.
28. 21 U.S.C. § 356b (a), (c) (2018).
 
      
 
         
     
 
         
      
      
   
           
  
         
 
            
         
       
    
 
    
     
    
   
         
      
      
 
           
  
 
         
   
 
               
            
            
            
              
         
            
        
  
174 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
drug, whether or not related to drug itself.29 “If adverse events appear to 
be systematic and serious, the FDA may withdraw a product from the 
market.”30 
Broken down in this manner, it is not difficult to understand why the 
process typically takes nearly a decade and costs billions of dollars to 
bring a drug to market. The FDA recognizes the need for measures
allowing for deviation from this standard procedure in emergency 
situations where it would not be feasible or beneficial to adhere to the
process strictly.
II.	' A NEED FOR SPEED: THE FDA’S FACILITATION OF ACCESS TO LIFE-
SAVING DRUGS
The FDA has taken steps to ensure that critically ill patients are able
to receive drugs that may not otherwise be available to them. It has done
so, first, by encouraging the production of such drugs, and second, by
enacting measures allowing patients to gain access to those drugs quickly 
and efficiently.
A. Special Designations and Accelerated Review
The FDA has enacted measures to encourage the development of
certain drugs, particularly those that “may represent the first available 
treatment for an illness, or ones that have a significant benefit over 
existing drugs.”31 These are drugs that manufacturers are often reluctant
to pursue under usual marketing conditions due, in large part, to financial 
risk. The FDA created special drug designations—fast track,32 
29. CDER Conversation: Tracking and Acting on Safety Data Throughout a Drug's
Lifecycle, FDA, https://www.fda.gov/drugs/news-events-human-drugs/cder-conversation-
tracking-and-acting-safety-data-throughout-drugs-lifecycle [https://perma.cc/S8CF-MN94].
30. Drug Development and Approval Process, supra note 4.
31. Development & Approval Process: Drugs, FDA, 
https://www.fda.gov/drugs/development-approval-process-drugs[https://perma.cc/R2QW-
WD29].
32. Fast track is a process designed to expedite the review of drugs that treat serious
conditions and fill an unmet medical need. This designation must be requested by the sponsor
and may be done so at any time during the development process. If the designation is received,
the drug and sponsor may be eligible for benefits including: “[m]ore frequent meetings with
FDA to discuss the drug’s development plan and ensure collection of appropriate data needed
to support drug approval,” “[m]ore frequent written communication from FDA about such
things as the design of the proposed clinical trials” and “[e]ligibility for accelerated approval 




     
 
      
     
     
 
      
          
            
            
    
    
      
   
    
 
          
          
        
         
 
  
               
             
          
           
      
  
   
           
      
    
         
         
        
             




1752020]	$ A HARD PILL TO SWALLOW
breakthrough therapy,33 and priority review34—meant to alleviate some of
the burden on the part of the manufacturer and help incentivize production 
of treatments by providing additional resources and expediting the overall
process.
Additionally, the FDA instituted accelerated approval, which
provides faster approval of drugs for serious conditions that fill an unmet 
medical need by relying on the use of surrogate endpoints during clinical
trials.35 This can considerably shorten the time required prior to receiving
FDA approval.
B.	' Expanded Access
The FDA’s special designations and accelerated review are 
predominantly directed toward facilitating a more efficient review process
on the manufacturing end. The FDA’s “expanded access,” or
33. The breakthrough designation is similar to that of fast track, but is specifically
“designed to expedite the development and review of drugs that are intended to treat a serious 
condition and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over available therapy on a clinically significant endpoint(s).” Breakthrough
Therapy, FDA, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-
approval-priority-review/breakthrough-therapy [https://perma.cc/L7PM-9NVM].
34. Priority review provides that the FDA’s goal is to take action on the application within
six months, rather than ten months under a standard review process. “A priority review
designation will direct overall attention and resources to the evaluation of applications for drugs 
that, if approved, would be significant improvements in the safety or effectiveness of the
treatment, diagnosis, or prevention of serious conditions when compared to standard 
applications.” Priority Review, FDA, https://www.fda.gov/patients/fast-track-breakthrough-
therapy-accelerated-approval-priority-review/priority-review [https://perma.cc/T79X-F8V6].
35. Clinical trials typically use endpoints that definitively demonstrate a clinical benefit
to a patient; accelerated approval, however, utilizes earlier markers that predict clinical benefit 
without yet proving it.
Drug companies are still required to conduct studies to confirm the anticipated 
clinical benefit. These studies are known as phase 4 confirmatory trials. If the 
confirmatory trial shows that the drug actually provides a clinical benefit, then the 
FDA grants traditional approval for the drug. If the confirmatory trial does not
show that the drug provides clinical benefit, [the] FDA has regulatory procedures 
in place that could lead to removing the drug from the market.
Accelerated Approval Program, FDA, https://www.fda.gov/drugs/information-healthcare-
professionals-drugs/accelerated-approval-program [https://perma.cc/8BNG-CN4G].
 
      
 
   
       
      
 
      
      
       
        
       
       
   
      
     
           
 
          
 
           
        
     
          
       
        
         
           
          
        
         
         
        
        
         
         
  
       
 
            
         
     
   
   
         
   
176 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
“compassionate use”36 program, codified in the FDCA,37 facilitates access 
on the patient end, allowing terminal patients to access medications that
are still being tested in clinical trials and, therefore, would not otherwise 
be available to them.38 
1. What is Expanded Access?
The expanded access program allows the use of an unapproved drug 
outside of a clinical trial by individuals with serious or life-threatening
conditions who do not meet the enrollment criteria for clinical trials. The 
FDA’s internal regulation allows expanded access submissions as either a
new IND or a protocol amendment to an existing IND.39 It provides for 
three categories of expanded access: (1) individual patients,40 (2) 
intermediate-size patient populations,41 and (3) widespread use.42 The
primary difference between the three categories is the number of patients
participating. Each of these categories contains a set of criteria that must
36. This Article uses the terms “expanded access” and “compassionate use”
interchangeably.  
37. 21 U.S.C. § 360bbb (2018). Under the FDCA, a patient can seek expanded access for
investigational products for the diagnosis, monitoring, or treatment of a serious disease or
condition if the following conditions are met:
(1) [T]he licensed physician determines that the person has no comparable or 
satisfactory alternative therapy available to diagnose, monitor, or treat the disease 
or condition involved, and that the probable risk to the person from the
investigational drug or investigational device is not greater than the probable risk
from the disease or condition; (2) the Secretary determines that there is sufficient
evidence of safety and effectiveness to support the use of the investigational drug 
or investigational device in the case described in paragraph (1); (3) the Secretary 
determines that provision of the investigational drug or investigational device will
not interfere with the initiation, conduct, or completion of clinical investigations
to support marketing approval; and (4) the sponsor, or clinical investigator, of the
investigational drug or investigational device submits to the Secretary a clinical 
protocol consistent with the [FDA requirements], describing the use of the
investigational drug or investigational device in a single patient or a small group
of patients.
Id. See also Expanded Access (Compassionate Use), FDA, 
https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/def 
ault.htm [https://perma.cc/8BJ6-9L8R].
38. See Jonathan P. Jarow et al., Overview of FDA’s Expanded Access Program for
Investigational Drugs, 51 THERAPEUTIC INNOVATION & REG. SCI. 177 (2017).
39. See 21 C.F.R. §§ 312.300–312.320 (2020).
40. 21 C.F.R. § 312.310 (2020).
41. 21 C.F.R. § 312.315 (2020).
42. See 21 C.F.R. § 312.320 (2020); see also Expanded Access (Compassionate Use),
supra note 37.
 
     
 
         
      
        
 
           
         
    
      
   
      
     
    
     
   
     
           
       
            
     
    
 
         
      
 
         
    
        
           
          
          
          
        
   
    
 
  
        
1772020] A HARD PILL TO SWALLOW
be met in order for a patient to receive approval.43 The most common
request is for individual use by a single patient, which includes use sought 
for emergency situations where treatment may be provided even before a
formal request has been submitted to the FDA.44 
Though meant to expedite and simplify the process to drug access,
the expanded access program comes with its own hurdles. Before an
individual patient can gain expanded access, many steps need to be 
undertaken. Among them, a licensed physician must confirm the patient’s
qualification for the program, gain industry cooperation, facilitate the 
process, and manage the treatment.45 Overall, the regulation attempts to
balance the competing interests of providing access to treatments that may 
ultimately prove successful (and for which normal approval would have 
come too late) with protecting patients from using drugs that may be 
harmful and actually worsen their conditions.46 
2. Challenges of Expanded Access
While federal regulations have provided a path for patients to gain
access to investigational drugs, this path is laden with various obstacles,
making it nearly impossible to access. Even after patients satisfy the
requirements as outlined by the regulations to become eligible for
expanded access, they are faced with hidden hurdles that further frustrate 
their journey.  
Ultimately, whether patients are actually able to receive the
investigational drugs rests on the manufacturer. The FDA cannot require
43. See 21 C.F.R. §§ 312.300–312.320 (2020); see also Expanded Access (Compassionate
Use), supra note 37.
44. Jonathan J. Darrow et al., Practical, Legal, and Ethical Issues in Expanded Access to
Investigational Drugs, 372 NEW ENG. J. MED. 279, 279 (2015). “Treatment is initially 
requested and authorized by telephone or other rapid means of electronic communication, and
may start immediately upon FDA authorization. The written submission (i.e., the individual 
patient expanded access IND) must be submitted within 15 business days of the telephone
authorization.” Expanded Access Categories for Drugs (Including Biologics), FDA, 
https://www.fda.gov/news-events/expanded-access/expanded-access-categories-drugs-
including-biologics [https://perma.cc/SK7S-R4QL].
45. Expanded Access: Information for Physicians, FDA, https://www.fda.gov/news-
events/expanded-access/expanded-access-information-physicians [https://perma.cc/Z6UV-
RL7H].
46. Darrow et al., supra note 44, at 279–80.
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a manufacturer to provide a drug.47 Therefore, manufacturers must
volunteer to provide the product, and there are many reasons for them to
refuse to do so. Primarily, there is a huge financial risk in providing the
drugs to patients before they are ready for the market. Although the FDA
allows companies to charge the direct costs of the drug to patients or their
insurance companies, there is fear that it may cause adverse publicity, 
because these costs will often be less than the price of the finalized drug
on the market.48 Additionally, it is unlikely that most insurance companies
would be willing to cover the costs of these drugs, leaving patients unable
to afford them on their own.49 Therefore, the FDA reports that most
manufacturers do not actually charge for their expanded access products.50 
Whereas some large corporations may be able to make up these losses 
through other revenue streams, smaller manufacturers may be relying
solely on the profits that these investigational products will eventually 
produce when brought to market. Similarly, larger companies may have 
the resources to supply excess drugs for expanded access patients, while
smaller companies may not have the resources to produce the drugs in
excess of what is needed for clinical trials.51 
Another obstacle is the administrative burden placed on the
pharmaceutical company as the sponsor. The FDA has estimated that it
requires approximately 120 hours of human labor for a company to
prepare a protocol for an intermediate-size patient population.52 Even for
47. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's Work to Mitigate
Shortages of Intravenous Drugs, Shorten Supply Disruptions and Better Predict Vulnerabilities
(May 31, 2018), https://www.fda.gov/news-events/press-announcements/statement-fda-
commissioner-scott-gottlieb-md-fdas-work-mitigate-shortages-intravenous-drugs-shorten
[https://perma.cc/V6FB-2BU2].




52. An intermediate-size population ranges from tens to hundreds of patients. Id. at 280.
The FDA attempted to address these concerns by making changes to the application process. In
its testimony to the Senate, the FDA’s then-Commissioner explained:
Last year, FDA implemented significant changes to streamline the process for
requesting expanded access for individual patients and promote greater 
transparency. We took a comprehensive and thorough look at the information
requested by the Agency—and slashed the number of required fields and
attachments to streamline this process. It now takes about 45 minutes to complete 
a single patient application form and requires just one attachment (compared with
 
     
 
     
          
       
      
          
      
   
       
            
      
        
      
  
       
 
    
      
      
      
           
     
        
      
     
       
         
 
        
     
              
           
   
  
   
       
         
    
      
     
    
 
1792020] A HARD PILL TO SWALLOW
large companies, it is a significant sacrifice, considering the alternative
ways the resources could be spent (i.e., designing and implementing
clinical trials). Small pharmaceutical companies will rarely be able to 
provide drugs through expanded access, as it is simply unlikely that they 
will have the physical capacity to dedicate the necessary resources.
For both small and large companies alike, all adverse events
experienced by patients through expanded access must be reported to the 
FDA. Once the FDA receives notice, it may choose to suspend clinical
trials on the drug.53 Adverse events could also affect the overall chance
of approval, lead to additional label warnings, or create negative 
publicity.54 Though suspension due to adverse events is a logical concern,
a review of almost 11,000 expanded access requests demonstrated that
only two drug programs were suspended due to adverse events observed 
in patients receiving expanded access, and these suspensions were only
temporary.55 
Physician participation is another major obstacle in the successful
implementation of the expanded access program. In order for an
individual to qualify for compassionate use, a sponsor must submit an IND
application on the patient’s behalf.56 Physicians typically serve as this
sponsor.57 Before taking on this responsibility, physicians would need to
be sure that they are able to handle the burden that lies ahead. In addition 
to completing the expanded access application, the physician will need to
obtain review and approval by an Institutional Review Board (“IRB”).58 
“The purpose of IRB review is to assure, both in advance and by periodic 
review, that appropriate steps are taken to protect the rights, safety and
welfare of humans participating as subjects in the research.”59 The FDA 
up to eight attachments previously required). The new form is accompanied by 
step-by-step instructions on how to complete it.
Examining Patient Access to Investigational Drugs: Hearing on H.R. 1020 and S. 204 Before
the Subcomm. on Health, H. Comm. on Energy and Commerce, 115th Cong. (statement of Scott 
Gottlieb, Commissioner, FDA) https://www.fda.gov/news-events/congressional-
testimony/examining-patient-access-investigational-drugs-10032017 [hereinafter Gottlieb].
53. FLATTEN, supra note 5.
54. Darrow et al., supra note 44, at 281.
55. Jarow et al., supra note 38, at 178.
56. 21 C.F.R. § 312.305(b) (2020).
57. See FLATTEN, supra note 5, at 9.
58. See generally 21 C.F.R. § 56 (2020).
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has acknowledged potential downsides of the process, namely, that the 
difficulty in convening a full review board may “impede prompt decision-
making and vital treatment.”60 Should the application be approved, the 
doctor must be willing to oversee the patient's treatment and work with 
industry participants in managing the use of the investigational drug.61 
This responsibility includes discussing risks and benefits with the patient
and obtaining all required informed consent.62 Not only do the doctors
have to follow FDA guidelines, but they also must abide by the dispensing 
and monitoring requirements imposed by the manufacturing company,
which typically mirror those of the ongoing clinical trials to minimize
unpredictable incidents and reactions.63 
Once an expanded access application is successfully submitted to the
FDA, the agency has thirty days to make a determination.64 According to
the FDA, “[e]mergency requests for individual patients are usually
granted immediately over the phone and non-emergency requests are 
generally processed within a few days.”65 Additionally, the FDA reports
that it approves ninety-nine percent of the applications that it receives for
expanded access.66 Critics argue that these statistics are meaningless, or 
at least misleading, because they only account for those applications that
were formally submitted to the FDA.67 What these numbers do not show
are the number of requestors and potential requestors who never even 
make it near that final stage.68 For example, there are instances wherein 
patients may submit requests directly to manufacturers, without reporting 
to the FDA; any denials stemming from those cases are not accounted for
by the FDA.69 Ultimately, though the FDA regulation was enacted in good
faith, it falls short in practical application.
60. Gottlieb, supra note 52.
61. Expanded Access: Information for Physicians, supra note 45.
62. Darrow et al., supra note 44, at 282.
63. FLATTEN, supra note 5, at 9.
64. 21 C.F.R. § 312.305(d)(1) (2020).
65. Gottlieb, supra note 52.
66. Caitlyn Martin, Questioning the “Right” in State Right to Try Laws: Assessing the
Legality and Effectiveness of These Laws, 77 OHIO L.J. 159, 171 (2016).
67. See FLATTEN, supra note 5, at 5.
68. See Martin, supra note 66, at 171; see also FLATTEN, supra note 5, at 5.
69. Ellen A. Black, State “Right to Try” Acts: A Good Start, But a Federal Act is
Necessary, 45 SW. L. REV. 719, 727 (2016).
 
     
 
        
      
       
       
       
             
        
      
            
 
   
        
   
    
           
        
      
         
         
        
      
        
      
       
        
 
          
      
 
            
             
         
        
      
 
      
       
 
1812020]	$ A HARD PILL TO SWALLOW
III. IF AT FIRST YOU DON'T SUCCEED: RIGHT TO TRY LAWS
The shortcomings of the expanded access program led to patient
activism aimed at acquiring greater patient access to investigational drugs
outside of the program. The Abigail Alliance for Better Access to 
Developmental Drugs (Alliance) is largely credited with catalyzing the 
movement.70 The group sued the FDA, arguing that the terminally ill have
a fundamental right to seek experimental treatment.71 Though the ensuing
legal battles are outside the scope of this Article, the Alliance created the 
foundation for the RTT movement that has continued to grow in the years
since.
A.	' State Right to Try Laws
In an attempt to fill the gaps in the FDA’s compassionate use
program, a majority of states have enacted legislation allowing 
manufacturers to provide experimental drugs to terminally ill patients 
without FDA approval.72 These state laws are colloquially known as RTT
laws and are created in response to what the states perceive as overly-strict 
FDA standards that may prevent patients from receiving potentially life-
saving treatments. Colorado started the movement in 2014.73 Currently,
there are forty-one states that have enacted RTT laws and a few others that
have legislation in the works.74 The states that have enacted RTT laws
include: Alabama, Alaska, Arizona, Arkansas, California, Colorado,
Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky,
Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi,
Missouri, Montana, Nebraska, Nevada, New Hampshire, North Carolina, 
North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina,
70. Valarie Blake, The Terminally Ill, Access to Investigational Drugs, and FDA Rules, 
15 AM. MED. ASS’N J. ETHICS 687, 687–89 (2013), https://journalofethics.ama-
assn.org/sites/journalofethics.ama-assn.org/files/2018-05/hlaw1-1308.pdf.
71. See generally Abigail Alliance for Better Access to Developmental Drugs v. Von
Eschenbach, 495 F.3d 695 (2007); Abigail Alliance for Better Access to Developmental Drugs
v. Von Eschenbach, 445 F.3d 470 (2006); Abigail Alliance for Better Access to Developmental
Drugs v. Von Eschenbach, 469 F.3d 129 (2006).
72. What is Right to Try?, RIGHTTOTRY, http://righttotry.org/about-right-to-try/
[https://perma.cc/U292-ABGL].
73. Martin, supra note 66, at 176 n.110.
74. Right to Try in Your State, RIGHTTOTRY, http://righttotry.org/in-your-state/
[https://perma.cc/2ZSR-FD2P].
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South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West
Virginia, Wisconsin, and Wyoming.75 
This movement was primarily spearheaded by the think tank
Goldwater Institute.76 The group’s initiative is to “allow terminal patients
access to investigational drugs that have completed basic safety testing,
thereby dramatically reducing paperwork, wait times and bureaucracy, 
and most importantly, potentially saving lives.”77 The Goldwater Institute 
has provided template legislation that some states have utilized.78 
75. ALA. CODE §§ 22-5D-1–22-5D-10 (2020); ALASKA STAT. § 08.64.367 (2020), ARIZ.
REV. STAT. ANN. §§ 36-1311-36-1314 (2020); ARK. CODE ANN. §§ 20-15-2101–20-15-2111 
(2020); CAL. CODE HEALTH & SAFETY CODE § 111548 (West 2020); COLO. REV. STAT. §§ 25-
45-101–25-45-108 (2020); CONN. GEN. STAT. § 20-14q (2020); FLA. STAT. § 499.0295 (2020);
GA. CODE ANN. §§ 31-52-1–31-52-10 (2020); IDAHO CODE §§ 39-9401 –39-9409 (2020); 410 
ILL. COMP. STAT. 649/10(5) (2020); IND. CODE §§ 16-42-26-1–16-42-26-5 (2020); IOWA CODE
§§ 144E.1–144E.9 (2020); KY. REV. STAT. ANN. § 217.5401-5408 (West 2020); LA. STAT.
ANN. §§ 40:1169.1–40:1169.6 (2019); ME. STAT. tit. 22, §§ 2671–2677 (2020); MD. CODE
ANN., HEALTH-GEN § 21-2b-01–21-B-06 (West 2019); MICH. COMP. LAWS §§ 333.26451– 
333.26457 (2020); MINN. STAT. § 151.375 (2020); MISS. CODE ANN. § 41-131-1 (2019); MO.
ANN. STAT. § 191.480 (West 2020); MONT. CODE ANN. §§ 50-12-101–50-12-110 (2019); NEB.
REV. STAT. §§ 71-9601–71-9611 (2020); NEV. REV. STAT. § 454.690 (2019); N.H. REV. STAT.
ANN. § 126-Z:1–126-Z:5 (2020); N.C. GEN. STAT. §§ 90-325–90-325.7 (2020); N.D. CENT.
CODE §§ 23-48-01 23-48-05 (2019); OHIO REV. CODE ANN. § 4729.89 (2020); OKLA. STAT.
tit. 63, §§ 3091.1–3091.7 (2020); OR. REV. STAT § 127.819 (West 2020); 35 PA. CONS. STAT.
AND CONS. STAT. ANN. §§ 10232.1–10232.7 (2020); S.C. CODE ANN. §§ 44-137-10 44-137-70 
(2020); S.D. CODIFIED LAWS §§ 34-51-1–34-51-10 (2020); TENN. CODE ANN. §§ 63-6-301–
63-6-310 (2020); TEX. HEALTH & SAFETY CODE ANN. §§ 489.001–489.151 (West 2019);
UTAH CODE ANN. §§ 58-85-101–58-85-105 (West 2020); VA. CODE ANN. §§ 54.1-3442.154.1-
3442.4 (2020); WASH. REV. CODE §§ 69.77.010–69.77.090 (2018); W. VA. CODE §§ 16-51-1– 
16-51-8 (2020); WIS. STAT. § 450.137 (2019); WYO. STAT. ANN. §§ 35-7-1801–35-7-1806 
(2020).
76. Sy Mukherjee, Trump Called for a ‘Right to Try’ Law During His State of the Union:
Here’s What That Means, FORTUNE (Feb. 1, 2018, 2:30 PM),
http://fortune.com/2018/02/01/trump-state-of-the-union-right-to-try/ [https://perma.cc/B9F8-
VTPH].
77. Christina Corieri, Everyone Deserves the Right to Try: Empowering the Terminally Ill
to Take Control of their Treatment, 266 GOLDWATER INST. 1, 1 (Feb. 11, 2014),
https://goldwaterinstitute.org/wp-content/uploads/cms_page_media/2015/1/28/ 
Right%20To%20Try.pdf [https://perma.cc/P5AX-3CQL].
78. Martin, supra note 66, at 175. Some key provisions in the template include:
To gain access to treatment, an individual must be an Eligible Patient, defined as
someone with an advanced Illness who has considered all other FDA-approved
treatment options, received recommendation from her physician, given informed
consent, and secured documentation from her physician that she meets the criteria 
of an Eligible Patient.
Id. Additionally, “[d]octors, hospitals, and manufacturers that do not follow the FDA approval
process are protected from disciplinary actions taken by a licensing board or disciplinary
subcommittee.” Id. at 176.
 
     
 
       
      
        
       
            
       
            
      
     
   
       
   
          
       
        
        
    
            
      
      
    
    
       
     
       
       
  
          
          
     
 
           
          
             
             
 
          
          
 
      
              
 
1832020] A HARD PILL TO SWALLOW
Though specific requirements vary by state, a majority of the
provisions are similar to those outlined in expanded access.79 There are,
however, some major differences between the FDA expanded access and
state RTT laws. For example, most states do not require approval by an
IRB.80 While this removes a significant barrier that would otherwise exist
in the expanded access program, it does so at the expense of the patient, 
who is no longer protected by the oversight and expertise of the review 
board. States likely expected that the circumvention of the FDA and the 
removal of the stricter requirements present in the expanded access
program would automatically increase the likelihood that terminally ill
patients receive access to investigational drugs. This assumption,
however, is misguided.
As with expanded access, the party ultimately responsible for the
success of the RTT laws is the drug manufacturer. Removing the FDA
from the process does not make it more likely that these companies will
cooperate. In fact, they would be less likely to participate. It is generally 
agreed upon by experts that drug companies are unlikely to make their
products available under state laws alone.81 They do not want to risk going
against the FDA, the agency that has the authority to control their
operations and the ability to bring their drugs to market. As with 
compassionate use, manufacturers run the risk of jeopardizing approval
for market entry should they choose to supply investigational drugs that
result in adverse conditions. Assisting the small group of patients who
request products under RTT laws may occur at the expense of the drug’s 
ultimate approval for use by the general population.82 It is highly unlikely
that many companies will sacrifice the time and resources necessary to
provide investigational drugs.
Ultimately, there are both strong supporters and opponents of the
RTT laws. Regardless, the mere existence of RTT laws in a majority of
states suggests the need for amendments to the expanded access program.  
79. Only patients who have exhausted all other treatment options can receive
investigational drugs under RTT laws; the patient’s physician must determine that the drug is
likely the patient’s best chance at survival. See FLATTEN, supra note 5, at 24. Michigan is an 
example of a state with such provisions. See MICH. COMP. LAWS ANN. § 333.26452(1) (West
2015).
80. FLATTEN, supra note 5, at 24; Carolyn Riley Chapman, et al., Oversight of Right-to-
Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs, 42 ETHICS &
HUMAN RES. 2, 5 (2020).
81. FLATTEN, supra note 5, at 24.
82. See supra Part II.B.2 (regarding the risks a manufacturer faces, should there be adverse
effects).
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Advocates for patients’ rights also pushed for the enactment of a federal
RTT act that would bridge the gap between the state acts and the agency
program.83 Indeed, the movement gained traction at the federal level, and
the platform was taken up by the Trump administration.  
B. Federal Right to Try Act
During Donald Trump’s first State of the Union address, the President
urged Congress to pass a RTT bill for terminally ill patients.84 He was
quoted saying: “We also believe that patients with terminal conditions
should have access to experimental treatments that could potentially save
their lives.”85 Trump essentially implied that terminally ill patients must
go to other countries in order to seek treatment when he said, “People who 
are terminally ill should not have to go from country to country to seek a 
cure—I want to give them a chance right here at home. It is time for the
Congress to give these wonderful Americans the right to try.”86 
Vice President Michael Pence has similarly been a supporter of the
RTT movement and has met with advocates to promote the cause.87 In
2015, as governor, he enacted Indiana’s RTT law.88 During his first month
as Vice President, he held a White House meeting with patients and 
families and vowed to help “get this done” on the federal level.89 With
the strong support of the administration, it was only a matter of time before
the RTT advocacy resulted in actionable measures by the federal 
legislature.
83. See Martin, supra note 66, at 185, 193.
84. Donald J. Trump, President of the United States, State of the Union Address (Jan.
30, 2018), https://www.whitehouse.gov/briefings-statements/president-donald-j-trumps-state-
union-address/ [https://perma.cc/7GNB-QYWS].
85. Id.; Mukherjee, supra note 76.
86. Mukherjee, supra note 76.
87. Thomas M. Burton, Trump Supports ‘Right to Try’ Law Expanding Access to
Experimental Drugs for Terminally Ill, WALL ST. J. (Jan. 31, 2018),
https://www.wsj.com/articles/trump-supports-right-to-try-law-expanding-access-to-
experimental-drugs-for-terminally-ill-1517420125 [https://perma.cc/V3MX-RZ4G].
88. IND. CODE ANN. § 16-42-26-4 (West 2020); 2015 Ind. Legis. Serv. P.L. 2-2015 
(H.E.A. 1065), http://iga.in.gov/legislative/2015/bills/house/1065#document-53b37ee0
[https://perma.cc/H2MX-U64A].
89. Elise Viebeck, House Approves ‘Right-to-Try’ Bill Giving Seriously Ill Patients
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In August 2017, the Senate unanimously passed the Wendler, 
Mongiello, McLinn, and Bellina Right to Try Act.90 The bill was
presented to the House of Representatives for vote on May 22, 2018, and 
was passed in identical form. On May 30, 2018, President Trump 
officially signed into law Public Act 115-176, the federal Right to Try 
Act.91 The Act amended Chapter V of the FDCA by inserting Section
561B—“Investigational Drugs for Use by Eligible Patients”—which
provides, in pertinent part:
Eligible investigational drugs provided to eligible patients in 
compliance with this section are exempt from sections 502(f),
503(b)(4), 505(a), and 505(i) of this Act, section 351(a) of the Public 
Health Service Act, and parts 50, 56, and 312 of title 21, Code of
Federal Regulations (or any successor regulations), provided that the 
sponsor of such eligible investigational drug or any person who
manufactures, distributes, prescribes, dispenses, introduces or delivers
for introduction into interstate commerce, or provides to an eligible 
patient an eligible investigational drug pursuant to this section is in 
compliance with the applicable requirements set forth in sections
312.6, 312.7, and 312.8(d)(1) of title 21, Code of Federal Regulations
(or any successor regulations) that apply to investigational drugs.92 
By definition, to be eligible for investigational drug access, a patient
must (1) have a life-threatening illness, (2) have exhausted all treatment 
options and be unable to participate in a clinical trial of the requested drug, 
and (3) provide to the treating physician written informed consent.93 
Therefore, the eligibility requirements are quite similar to those present in
the expanded access program. The most significant distinction, and the
one that causes concern among critics, is the exclusion of the FDA in the 
process.
C. Concerns Surrounding the RTT Act
When the RTT Act was first introduced in the Senate, it was a cause
of concern for the drug industry, public health advocates, and the FDA,
all of whom were worried that it could undermine patient safety and drug 
90. Right to Try Act, S. 204, 115th Cong. (2017).




      
 
          
          
    
      
          
 
           
              
        
    
   
       
         
       
     
         
 
          
       
        
             
          
          
            
      
 
 
             
         
          
          
            
 
 
          
           
        
 
    
        
186 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
development processes.94 A key provision of this bill was that
manufacturers and physicians would not be required to obtain FDA
approval prior to treating patients, though they would still be required to 
report any adverse effects that occurred.95 The FDA’s then-
Commissioner, Scott Gottlieb, urged the Senate to amend the bill’s
language to maintain the FDA’s oversight power over treatments.96 
Many of the concerns expressed by critics regarding the state RTT
laws are prevalent in the federal law. Critics worry that the RTT laws will
threaten FDA standards “by allowing wider use of untested drugs in an
unnecessarily broad population.”97 It has been reported that 
approximately ten to eleven percent of compassionate use proposals
submitted to the FDA require modifications to their dosages, informed
consent procedures, and safety monitoring.98 RTT laws could lead to less
safe and less effective use of experimental drugs. Public health advocates 
argue that the majority of terminally ill patients’ needs are already 
satisfied through the compassionate use program and that the creation of 
94. Letter from Am. Cancer Society Cancer Action Network et al., to Paul Ryan, Speaker
& Nancy Pelosi, Minority Leader (Feb. 6, 2018), https://www.fightcancer.org/ 
sites/default/files/National%20Documents/February%20Right%20to%20Try%20Coalition%2 
0Letter%20-%20Final.pdf [https://perma.cc/K924-S4GB]. In a letter sent to the House of
Representatives, a group of forty advocacy groups expressed their concern with the proposed
House and Senate bills. They wrote, in relevant part:
Our organizations support patient access to unapproved therapies. However,
the Right to Try bills currently under consideration in the House do not effectuate
policy changes that would afford our patients greater access to promising 
investigational therapies.
. . . We do not believe S.204 or H.R.878 would successfully increase access to 
promising investigational therapies for those in need. Both of these bills remove
the Food and Drug Administration (FDA) from the initial approval process for
accessing an investigational therapy outside of a clinical trial. Removing FDA
from this process is not likely to facilitate increased access to investigational
therapies.
Id.
95. Right to Try Act, Pub. L. No. 115-176, 132 Stat. 1372 (2018).
96. Carlos Ballesteros, Critics Warn Trump’s Koch-Backed ‘Right to Try’ Bill is
Dangerous for Patients, NEWSWEEK (Jan. 31, 2018, 3:36 PM),
http://www.newsweek.com/koch-brothers-conservative-groups-behind-trumps-right-try-bill-
796185 [https://perma.cc/NM5Q-SZF9].
97. Burton, supra note 87.
98. Mukherjee, supra note 76; Burton, supra note 87.
 
     
 
          
     
      
         
  
       
 
     
         
             
           
        
      
      
     
       
       
       
       
         
    
 
          
          
  
 
    
 
      
             
          
            
         
       
       
             
             
      
              
         
  
1872020] A HARD PILL TO SWALLOW
RTT laws could ultimately cause more harm than good.99 Additionally,
critics worry about the lack of recourse for patients who experience 
adverse effects, as the RTT laws limited their ability to sue for malpractice 
or negligence.100 Some have gone as far as to say that RTT laws
“immunize physicians administering unapproved medications and the 
companies behind the drugs and treatment.”101 The federal law contains
one such “no liability” provision.102 
Similarly, the impediments to the success of the expanded access
program have not been adequately addressed, if at all, by the federal law.
Although the RTT Act grants a patient the right to seek access to an
experimental drug, as is the case with compassionate use, it does not
require the manufacturer to provide the drug. Many of the reservations 
that manufacturers may have under the expanded access program remain
in the forefront under the federal law. For instance, the concern that 
providing the drug to patients outside of clinical trials could lead to
negative clinical outcomes and disrupt the approval process is not entirely 
alleviated by the new legislation. Although the law prevents this data from
being used unless it is deemed “‘critical to determining safety,’ bad
outcomes might give the FDA pause and delay the approval of drugs that
might otherwise be available sooner.”103 For these reasons, manufacturers
are still likely to withhold the drug.
99. Stephen Barlas, "Right to Try" Legislation Moving Through Congress: But Drug
Companies and Some Patient Groups Want Changes, 42 PHARMACY & THERAPEUTICS 739,
739, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720486/ [https://perma.cc/WGP4-
UP74].
100. Ballesteros, supra note 96.
101. Id.
102. The Act provides, in relevant part:
With respect to any alleged act or omission with respect to an eligible
investigational drug provided to an eligible patient pursuant to section 561B of the
Federal Food, Drug, and Cosmetic Act and in compliance with such section, no
liability in a cause of action shall lie against—(A) a sponsor or manufacturer; or 
(B) a prescriber, dispenser, or other individual entity (other than a sponsor or 
manufacturer), unless the relevant conduct constitutes reckless or willful
misconduct, gross negligence, or an intentional tort under any applicable State law.
Pub. L. No. 115-176 § 561B(b)(1). It also protects the parties from liability for a determination 
not to provide access to an IND. Id. at § 561B(b)(2).
103. Morten Wendelbo & Timothy Callaghan, What is “Right to Try” and Will it Help




      
 
      
      
    
        
        
      
       
     
          
    
    
       
       
      
     
   
            
    
    
          
           
         
   
 
            
         
          
      
 
 
     
        
      
 
        
    
 
 
         
       
  
188 WESTERN NEW ENGLAND LAW REVIEW [Vol. 42:169
IV. DRUG ACCESS DURING THE CORONAVIRUS PANDEMIC104 
In early March of 2020, President Trump began promoting
hydroxychloroquine and chloroquine as potential cures for the 
coronavirus.105 These drugs, however, are only FDA-approved to treat
malaria, lupus, and rheumatoid arthritis,106 thus renewing the discussion
surrounding access of nonapproved drugs in emergency situations. So far, 
it seems RTT will play but a small role, if any, in the discussion as the
nation continues its fight against COVID-19.
On March 17, 2020, the Goldwater Institute released a statement
urging policymakers to expand RTT even further amid the new
coronavirus outbreak.107 In its statement, the group wrote: 
For patients who have either become infected, are at high risk, or
simply wish to inoculate themselves from the COVID-19 virus,
patients, under their physician’s care, should be allowed to access
treatments and vaccines prior to government approval, if and when 
they are made available by manufacturers.108 
There seems to be little need for this RTT expansion, however, as the
FDA has acted swiftly in allowing for the exploration of
hydroxychloroquine and chloroquine as treatment options for the 
coronavirus, despite there being a severe lack of empirical data.109 On
March 28, 2020, the FDA issued an emergency use authorization (EUA)
for both drugs, allowing them to be “donated to the Strategic National 
Stockpile to be distributed and prescribed by doctors to hospitalized teen
104 Due to the constantly evolving nature of the coronavirus pandemic response, the
reader should note that the following discussion reflects the state of affairs as of May 2020.
105. Philip Bump, The Rise and Fall of Trump’s Obsession with Hydroxychloroquine, 
WASH. POST (Apr. 24, 2020, 2:17 PM), https://www.washingtonpost.com/ 
politics/2020/04/24/rise-fall-trumps-obsession-with-hydroxychloroquine/
[https://perma.cc/RR3F-UFKZ].
106. FDA, FREQUENTLY ASKED QUESTIONS ON THE EMERGENCY USE AUTHORIZATION 
(EUA) FOR CHLOROQUINE PHOSPHATE AND HYDROXYCHLOROQUINE SULFATE FOR CERTAIN
HOSPITALIZED COVID-19 PATIENTS, 1 (2020) [hereinafter FREQUENTLY ASKED QUESTIONS], 
https://www.fda.gov/media/136784/download [https://perma.cc/NPK2-WZR7].
107. GOLDWATER INST., Now is the Time to Expand Right to Try, IN DEFENSE OF 
LIBERTY (Mar. 17, 2020), https://indefenseofliberty.blog/2020/03/17/now-is-the-time-to-
expand-right-to-try/ [https://perma.cc/TF8Y-HBA4].
108. Id.
109. William Feuter, WHO Says There's "No Empirical Evidence" Trump-Touted
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and adult patients with COVID-19, as appropriate, when a clinical trial is
not available or feasible.”110 Additionally, the FDA is expected to
authorize a similar EUA for the experimental antiviral drug remdesivir.111 
In certain types of emergencies, the FDA may issue an EUA to 
facilitate access to medical countermeasures (drugs, biologics, vaccines, 
and devices) that can be used to diagnose, treat, or prevent a serious
disease or condition in a public health emergency.112 Before authorizing
such use, the FDA “decides whether the use of the product is likely to [be]
more helpful than harmful for the emergency use; i.e., the FDA determines
that the known and potential benefits of the medical products for their 
intended uses outweigh their known and potential risks.”113 
The FDA’s ability to collect data on the experimental treatments for
COVID-19 brings to the forefront the key pitfall of the federal RTT law.
Under RTT, clinical data would not be formally reported unless adverse
events took place.114 Scientists had already been skeptical of the use of
hydroxychloroquine and chloroquine when reports first suggested that
they may be effective in treating the coronavirus, “noting the lack of data
on the drugs’ efficacy for coronavirus care and worries that it would
siphon medication away from patients who need it for other conditions, 
calling instead for the FDA to pursue its usual clinical trials.”115 Even
with the FDA’s explicit involvement by issuing the EUA, the skepticism
remains. “[O]utside of a clinical trial, it can be hard to assess the drug’s 
value, especially when it is being given to a variety of patients, of different
ages and medical conditions, and at different points in their disease,” a 
110. Emergency Use Authorization, FDA, https://www.fda.gov/emergency-preparedness-
and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
[https://perma.cc/RA8B-GTAF].
111. Maggie Fox, et al., FDA Will Reportedly Authorize Use of Remdesivir for Covid-19 
After Trial Shows “Positive Effect” on Recovery Time, CNN (April 30, 2020, 5:03 AM),
https://www.cnn.com/2020/04/29/health/gilead-sciences-remdesivir-covid-19-
treatment/index.html [https://perma.cc/3HKA-SZDW].
112. See 21 U.S.C. § 360bbb–3(a)(1) (2018); see also Emergency Use Authorization, 
supra note 109; HHS Accepts Donations of Medicine to Strategic National Stockpile as Possible




113. See FREQUENTLY ASKED QUESTIONS, supra note 106.
114. See Pub. L. No. 115-176 § 561B(d)(1).
115. Dan Diamond, FDA Issues Emergency Authorization of Anti-Malaria Drug for
Coronavirus Care, POLITICO (Mar. 29, 2020), https://www.politico.com/news/2020/03/29/fda-
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health expert has explained.116 The FDA’s involvement is critical,
however, as it is “expected to facilitate more access to the drugs by 
allowing more donations, and a second EUA is under consideration that
would allow more manufacturers to produce it.”117 This, presumably,
would allow for important results of the drugs to amass while clinical trials
are underway.118 Ultimately, it remains to be seen whether RTT laws will
find a place alongside the EUA in the government's efforts to find an
effective treatment for COVID-19.
CONCLUSION
Amidst the complex statutory and regulatory landscapes on drug
development, approval, and access, it is likely that there will be an ensuing 
policy struggle between allowing individuals liberal access and providing 
necessary governmental oversight and restrictions. There is perhaps no 
setting more apt for this debate to unfold than during a global health
emergency. As health officials work tirelessly to combat this pandemic,
governments are faced with the high-stakes challenge of balancing speed
of access with safety. The discussions on expanded access, RTT, and the 
general policy debates regarding drug access will surely continue, if not
be reinvigorated, when the pandemic subsides.
116. Katie Thomas, Trump Calls this Drug a ‘Game Changer.’ Doctors Aren’t So Sure., 
N.Y. TIMES (Apr. 17, 2020), https://www.nytimes.com/2020/04/17/health/trump-
hydroxychloroquine-coronavirus.html [https://perma.cc/RMJ4-VB3V].
117. Diamond, supra note 115.
118. See U.S. Nat’l Library of Med., Search of: COVID-19, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/results?cond=COVID-19 (last visited May 20, 2020)
[https://perma.cc/P5AX-3CQL].
